306 related articles for article (PubMed ID: 25594147)
1. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Kunos C; Deng W; Dawson D; Lea JS; Zanotti KM; Gray HJ; Bender DP; Guaglianone PP; Carter JS; Moore KN
Int J Gynecol Cancer; 2015 Mar; 25(3):484-92. PubMed ID: 25594147
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
Thaker PH; Salani R; Brady WE; Lankes HA; Cohn DE; Mutch DG; Mannel RS; Bell-McGuinn KM; Di Silvestro PA; Jelovac D; Carter JS; Duan W; Resnick KE; Dizon DS; Aghajanian C; Fracasso PM
Ann Oncol; 2017 Mar; 28(3):505-511. PubMed ID: 27998970
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
[No Abstract] [Full Text] [Related]
5. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
Pipas JM; Meyer LP; Rhodes CH; Cromwell LD; McDonnell CE; Kingman LS; Rigas JR; Fadul CE
J Neurooncol; 2005 Feb; 71(3):301-5. PubMed ID: 15735921
[TBL] [Abstract][Full Text] [Related]
6. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.
Shimada M; Sato S; Oishi T; Itamochi H; Kigawa J; Takeshima N; Aoki D; Aoki Y; Nambu Y; Ochiai K
Int J Clin Oncol; 2016 Oct; 21(5):969-974. PubMed ID: 27142771
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Tiersten AD; Selleck MJ; Hershman DL; Smith D; Resnik EE; Troxel AB; Brafman LB; Shriberg L
Gynecol Oncol; 2004 Feb; 92(2):635-8. PubMed ID: 14766258
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
Miller DS; Blessing JA; Kilgore LC; Mannel R; Van Le L
Am J Clin Oncol; 2000 Aug; 23(4):355-7. PubMed ID: 10955863
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
Zighelboim I; Wright JD; Gao F; Case AS; Massad LS; Mutch DG; Powell MA; Thaker PH; Eisenhauer EL; Cohn DE; Valea FA; Alvarez Secord A; Lippmann LT; Dehdashti F; Rader JS
Gynecol Oncol; 2013 Jul; 130(1):64-8. PubMed ID: 23591400
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
11. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.
Brown JV; Peters WA; Rettenmaier MA; Graham CL; Smith MR; Drescher CW; Micha JP
Gynecol Oncol; 2003 Feb; 88(2):136-40. PubMed ID: 12586592
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
Pratz KW; Rudek MA; Gojo I; Litzow MR; McDevitt MA; Ji J; Karnitz LM; Herman JG; Kinders RJ; Smith BD; Gore SD; Carraway HE; Showel MM; Gladstone DE; Levis MJ; Tsai HL; Rosner G; Chen A; Kaufmann SH; Karp JE
Clin Cancer Res; 2017 Feb; 23(4):899-907. PubMed ID: 27551000
[No Abstract] [Full Text] [Related]
13. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Ramasubbaiah R; Perkins SM; Schilder J; Whalen C; Johnson CS; Callahan M; Jones T; Sutton G; Matei D
Gynecol Oncol; 2011 Dec; 123(3):499-504. PubMed ID: 21955480
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
15. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
[TBL] [Abstract][Full Text] [Related]
16. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.
Choi CH; Kim TJ; Lee SJ; Lee JW; Kim BG; Lee JH; Bae DS
Int J Gynecol Cancer; 2006; 16(3):1157-64. PubMed ID: 16803500
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Lilenbaum RC; Ratain MJ; Miller AA; Hargis JB; Hollis DR; Rosner GL; O'Brien SM; Brewster L; Green MR; Schilsky RL
J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
